Clinical Trial Update: SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous SB-681323 in subjects at risk of acute lung injury or acute respiratory distress syndrome has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• SB-681323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Injury, Acute | Phase 2 | Status: COMPLETED | Results posted: 2017-10-18